This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Svendsen B, Aarseth JH, Nyland H, Myhr K-M.Economic analysis of treatment of multiple sclerosis with Tysabri alternative to standard disease-modifying drugs in Norway. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 12th Annual Conference on Rehabilitation in MS: [1 page], 11 Oct 2007. Available from: URL: http://www.akm.ch/ectrims2007
Rights and permissions
About this article
Cite this article
Natalizumab may be cost effective for MS in Norway. Pharmacoecon. Outcomes News 542, 6 (2007). https://doi.org/10.2165/00151234-200705420-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705420-00010